Khoury Mitri K, Stranz Amelia R, Liu Bo
Department of Surgery, Division of Vascular and Endovascular Surgery, University of Texas Southwestern Medical Center, Dallas, United States.
Department of Surgery, Division of Vascular Surgery, University of Wisconsin-Madison, WI, United States.
Cardiol Cardiovasc Med. 2020 Aug;4(4):498-514. doi: 10.26502/fccm.92920146. Epub 2020 Aug 31.
Aortic aneurysms are defined as dilations of the aorta greater than 50 percent. Currently, the only effective treatment for aortic aneurysms is surgical repair, which is recommended only to those that meet criteria. There is no available pharmaceutical therapy to slow aneurysm growth and thus prevent lethal rupture. The development of a number of murine models has allowed in depth studies of various cellular and extracellular components of aneurysm pathophysiology. The identification of key therapeutic targets has resulted in several clinical trials evaluating pharmaceutical candidates to treat aneurysm progression. In this review, we focus on providing recent updates on developments in murine models of aortic aneurysm. In addition, we discuss recent studies of the various cellular and extracellular components of the aorta along with the abutting aortic structures that contribute to aneurysm development and progression.
主动脉瘤被定义为主动脉直径扩张超过50%。目前,主动脉瘤唯一有效的治疗方法是手术修复,仅推荐给符合标准的患者。尚无可用的药物疗法来减缓动脉瘤生长并预防致命破裂。多种小鼠模型的建立使得对动脉瘤病理生理学的各种细胞和细胞外成分进行深入研究成为可能。关键治疗靶点的确定促使了多项评估治疗动脉瘤进展的候选药物的临床试验。在本综述中,我们重点介绍主动脉瘤小鼠模型的最新进展。此外,我们还讨论了主动脉各种细胞和细胞外成分以及毗邻主动脉结构在动脉瘤发生和发展中的最新研究情况。